公开(公告)号：US20250136984A1

公开(公告)日：2025-05-01

申请号：US18904968

申请日：2024-10-02

Applicant: Hoffmann-La Roche Inc.

Inventor： Ravi JAGASIA ,  Lars JOENSON ,  Søren RASMUSSEN ,  Disa TEHLER ,  Dorthe Vang LARSEN ,  Jesper WORM

IPC: C12N15/113 ,  A61P25/00

Abstract: The present invention relates to oligonucleotides which up-regulate or restore the expression of progranulin in cells, and their use in the treatment of neurological disorders, and disorders associated with progranulin haploinsufficiency.

公开(公告)号：US20250136639A1

公开(公告)日：2025-05-01

申请号：US18645245

申请日：2024-04-24

Applicant: Hoffmann-La Roche Inc.

Inventor： ROBERTO FALKENSTEIN ,  BERNHARD SPENSBERGER

IPC: C07K1/18 ,  B01D15/36 ,  C07K14/505

Abstract: Herein is reported a method for the purification of a protein comprising erythropoietin and a single poly (ethylene glycol) residue from reaction by-products or not reacted starting material by a cation exchange chromatography method. It has been found that by employing a cation exchange Toyopearl® SP-650 chromatography material and employing a second wash step with an increased pH value compared to the first wash step a fusion protein of erythropoietin and a single poly (ethylene glycol) residue can be obtained in a single step with high purity and yield and suitability for large scale applications.

公开(公告)号：US20250134900A1

公开(公告)日：2025-05-01

申请号：US19009912

申请日：2025-01-04

Applicant: Hoffmann-La Roche Inc. ,  Chugai Seiyaku Kabushiki Kaisha

Inventor： Susanne MEIER ,  Carsten BRUESEWITZ

IPC: A61K31/5377 ,  A61K9/48 ,  A61K47/14 ,  A61K47/22 ,  A61K47/26

Abstract: The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.

公开(公告)号：US20250129179A1

公开(公告)日：2025-04-24

申请号：US18813302

申请日：2024-08-23

Applicant: Hoffmann-La Roche Inc.

Inventor： Joerg Benz ,  Christian Klein ,  Stefan Klostermann ,  Ekkehard Moessner ,  Johannes Sam ,  Pablo Umaña ,  Lydia Jasmin Hanisch ,  Alexander Bujotzek ,  Wei Xu

IPC: C07K16/30 ,  A61K35/00 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C07K16/32

Abstract: The present invention generally relates to antibodies that bind to HLA-A2/WTI, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

公开(公告)号：US12281153B2

公开(公告)日：2025-04-22

申请号：US17017942

申请日：2020-09-11

Applicant: Hoffmann-La Roche Inc.

Inventor： Christina Claus ,  Claudia Ferrara Koller ,  Christian Klein ,  Johannes Sam ,  Pablo Umana

IPC: C07K14/705 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40

Abstract: The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.

公开(公告)号：US12281124B2

公开(公告)日：2025-04-22

申请号：US18475065

申请日：2023-09-26

Applicant: Hoffmann-La Roche Inc.

Inventor： Charles Bell ,  Joerg Benz ,  Luca Gobbi ,  Uwe Grether ,  Katrin Groebke Zbinden ,  Benoit Hornsperger ,  Buelent Kocer ,  Carsten Kroll ,  Bernd Kuhn ,  Marius Daniel Rinaldo Lutz ,  Fionn O'Hara ,  Hans Richter ,  Martin Ritter ,  Didier Rombach ,  Martin Kuratli

IPC: C07D498/04 ,  C07D519/00

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

公开(公告)号：US20250115607A1

公开(公告)日：2025-04-10

申请号：US18985716

申请日：2024-12-18

Applicant: Hoffmann-La Roche Inc.

Inventor： Guillaume DÉCORET ,  Katrin GROEBKE ZBINDEN ,  Wolfgang HAAP ,  Lukas KREIS ,  Xavier LUCAS CABRÉ ,  Etienne RAUBER

IPC: C07D471/04 ,  A61K31/444 ,  A61K31/501 ,  A61K31/5383 ,  C07D519/00

Abstract: The invention relates to a compound of formula (I) wherein A1, R1, R2, R3, R4 and R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

公开(公告)号：US20250114775A1

公开(公告)日：2025-04-10

申请号：US18984468

申请日：2024-12-17

Applicant: Hoffmann-La Roche Inc.

Inventor： Kurt PUENTENER ,  Etienne TRACHSEL

IPC: B01J31/24 ,  B01J31/22 ,  B01J37/02 ,  B01J37/03 ,  B01J37/06 ,  B01J37/08 ,  C07F15/00

Abstract: The invention comprises a process for the preparation of a [Ru(OAc)2(Ligand)] catalysts of the formula I wherein R1 is C1-6 alkyl and R3 is hydrogen or C1-6 alkyl and R4 is hydrogen or C1-6-alkoxy.
[Ru(OAc)2(Ligand)] catalysts are versatile hydrogenation catalysts.

公开(公告)号：US20250109149A1

公开(公告)日：2025-04-03

申请号：US18885056

申请日：2024-09-13

Applicant: Hoffmann-La Roche Inc.

Inventor： Roland MEIER ,  Urs SCHWITTER ,  Anne DE PAEPE ,  Peter KUEHL ,  Juergen THUN ,  Frank STOWASSER

IPC: C07D519/00

Abstract: The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.

公开(公告)号：US20250092128A1

公开(公告)日：2025-03-20

申请号：US18901300

申请日：2024-09-30

Applicant: Hoffmann-La Roche Inc.

Inventor： Peter BRUENKER ,  Martina GEIGER ,  Christian KLEIN ,  Pablo UMAÑA

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/42

Abstract: The present invention generally relates to improved Protease-activatable antigen-binding molecules that comprise an anti-idiotype-binding moiety which reversibly masks a CD3 antigen binding moiety of the molecule. Furthermore, the invention relates to novel Protease-cleavable peptide linkers and their used in such Protease-activatable antigen-binding molecules. In addition, the present invention relates to polynucleotides encoding such Protease-activated T cell binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the Protease-activated T cell binding molecules of the invention, and to methods of using the same, e.g., in the treatment of disease.